Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy is a phase 2, randomised interventional study registered as NCT06569368 by M.D. Anderson Cancer Center, with a registry enrolment figure of 60 participants, started 2024-07-10 and due to reach its primary completion in 2027-10-31. Interventions recorded: Metronidazole. Conditions listed: Rectal Adenocarcinoma. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* Participants with locally advanced rectal cancers (T3, T4, or N+ disease) with decision to treat with total neoadjuvant therapy". Sites: United States. No results are recorded here; the registry entry is the source.